ClinicalTrials.gg
CompletedNCT03246880Updated Aug 11, 2017

Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients

A Phase 3 interventional study of Tamsulosin 0.2mg and Tadalafil 5mg in Benign Prostatic Hyperplasia, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2017-08-11.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
13th of 48
455 · median 118
Started
2015
with 4 others
Phase 3
11 of 48
1 open now
Registered
26th of 48
by date

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 13th largest by enrollment, is one of 5 that started in 2015, is one of 11 in phase 3, and was the 26th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[Visit 1]

  1. Male Aged of 45 or above
  2. Patients must have a diagnosis of Benign Prostatic Hyperplasia
  3. IPSS(International Prostate Symptom Score) questionnaire total score ≥ 13
  4. Signed and dated document indicating that the patient

[Visit 2]

  1. IPSS(International Prostate Symptom Score) questionnaire total score ≥ 13
  2. 15mL/s ≥ Qmax ≥ 4mL/s, if voided volume ≥ 120ml
  3. PVR(post-void residual urine volume) ≤ 250ml

Exclusion criteria

Exclusion Criteria:

  1. Patients have ever taken Finasteride in 3 months or Dutasteride in 6 months
  2. Patients with prostate cancer or PSA > 10ng/ml
  3. Patients with other disease which could have influence on urine flow rate except BPH(benign prostatic hyperplasia )
  4. Patients with a history of operation on prostate which could have influence on the result and need to have surgery.
  5. Patients with acute urinary retention in 3months
  6. Patients with a history of drug or alcohol abuse within 6 months
  7. Patients have cardiovascular disease or associated disease which is not controlled.
  8. Patients who need to take Nitrates, alpha blocker, Nitric Oxide Donor
  9. Patients with orthostatic hypotension
  10. Patients with a history micturition syncope
  11. Patients with severe or malignant retinopathy
  12. Patients have a visual disturbance by Non-arteritic anterior ischemic optic neuropathy
  13. Patients with a congestive disease like galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
  14. Serum creatinine > upper Normal Limit*2, /ALT > upper Normal Limit*3
  15. Patient with uncontrolled diabetes(>9%)
  16. Patients have a history of malignant tumor within 5 years
  17. Patients have reaction on this drug.
  18. Patients treated with other product within 4 weeks at first time taking the investigational product
  19. Not eligible to participate for the study at the discretion of investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
455 participants (actual)

Study arms

  • Experimental
    Tamsulosin 0.2mg+Tadalafil 5mg

    Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.

    Drug: Tamsulosin 0.2mg · Drug: Tadalafil 5mg

  • Active comparator
    Tamsulosin 0.2mg

    Tamsulosin 0.2mg, po, q.d.

    Drug: Tamsulosin 0.2mg

  • Active comparator
    Tadalafil 5mg

    Tadalafil 5mg, po, q.d.

    Drug: Tadalafil 5mg

Interventions

06

What researchers measure

Primary outcomes

  1. The mean change of the total score on IPSS questionnaire(International Prostate Symptom Score )

    Time frame: From baseline at week 12

Secondary outcomes

  1. The mean change of scores on three questionnaire, Qmax(maximum flow rate(urine), PVR(post-void residual urine volume)

    IPSS questionnaire(International Prostate Symptom Score ), IIEF-5(International Index of Erectile Function-5) questionnaire Change in score, ICIQ-MLUTS(International Consultation on Incontinence Modular Questionnaire-Male Lower Urinary Tract Symptoms) questionnaire Change in score

    Time frame: From baseline at week 12

  2. The mean change of scores on IPSS ( International Prostate Symptom Score ), ICIQ-MLUTS( International Consultation on Incontinence Modular Questionnaire-Male Lower Urinary Tract Symptoms) questionnaire Change in score

    Time frame: From baseline at week 8

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Apr 2016, 7 months.

Of 17 phase 3 interventional studies under Prostatic Hyperplasia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Aug 11, 2017
StartActual
Sep 2015
Primary completionActual
Apr 2016
CompletionActual
May 2016
Last update
Aug 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03246880
Responsible party
Sponsor
First posted
Aug 11, 2017
Start date
Sep 2015
Primary completion
Apr 2016
Completion
May 2016
Last update
Aug 11, 2017

Study contacts

Myung-Soo Choo, M.D., Ph.D
principal investigator · Asan Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamsulosin · Tadalafil

Start the discussion